- Impact of intra-partum Azithromycin on carriage of group A streptococcus in The Gambia: a
posthoc analysis of a double-blind randomized placebo-controlled trial
Isatou Jagne¹
Email: <u>ijcox@mrc.gm</u>
Alexander J. Keeley³

- 92 **posthoc analysis of a double-blind randomized placebo-controlled trial**

1 Isatou Jagne¹

2 Email: <u>ijcox@mrc.gm</u>

2 Alexander J. Keeley³

2 Email: <u>a.keeley@sheffield.ac.uk</u>

2 Abdoulie Bojang¹
- Isatou Jagne $¹$ </sup>
- 4 Email: <u>ijcox@mrc.gm</u>
5 Alexander J. Keeley³
6 Email: <u>a.keeley@shef</u>
7 Abdoulie Bojang¹
8 Email: <u>ambojang@mr</u>
9 Bully Camara¹
- 4 5 6 7 8 0 Alexander J. Keeley³
- 6 7 8 9 0 1 6 Email: <u>a.keeley@sheffield.ac.uk</u>

7 Abdoulie Bojang¹

8 Email: <u>ambojang@mrc.gm</u>

8 Bully Camara¹

0 Email: <u>bcamara@mrc.gm</u>

1 Edrissa Jallow¹
- Abdoulie Bojang $¹$ </sup>
- 89012 8 Email: <u>ambojang@mrc.gm</u>
9 Bully Camara¹
0 Email: <u>bcamara@mrc.gm</u>
1 Edrissa Jallow¹
2 Email: <u>edjallow@mrc.gm</u>
8 Elina Senghore¹
- Bully Camara¹
-
- Edrissa Jallow¹
- 10 Email: <u>bcamara@mrc.gm</u>

11 Edrissa Jallow¹

12 Email: <u>edjallow@mrc.gm</u>

13 Elina Senghore¹

14 Email: <u>esenghore@mrc.gr</u>

15 Claire Oluwalana¹ 12 Email: <u>edjallow@mrc.gm</u>

13 Elina Senghore¹

14 Email: <u>esenghore@mrc.gr</u>

15 Claire Oluwalana¹

16 Email: <u>coluwalana@mrc.gr</u>

5 Saikou Y. Bah^{1,3}
- 0 1 2 3 4 5 12
13
14
15
16
17 Elina Senghore $¹$ </sup>
-
- Claire Oluwalana $¹$ </sup>
-
- 14
15
16
17
18
19 16
17
18
19
20 Saikou Y. Bah 1,3
- 14 Email: <u>esenghore@mrc.gm</u>

15 Claire Oluwalana¹

16 Email: <u>coluwalana@mrc.gr</u>

17 Saikou Y. Bah^{1,3}

18 Email: <u>s.bah@sheffield.ac.u</u>

19 Claire E. Turner³ 16 Email: <u>coluwalana@mrc.gm</u>

17 Saikou Y. Bah^{1,3}

18 Email: <u>s.bah@sheffield.ac.ul</u>

19 Claire E. Turner³

20 Email: <u>c.e.turner@sheffield.</u>

21 Abdul Karim Sesay¹ --
18
19
20
21
22
22 18 Email: <u>s.bah@sheffield.ac.uk</u>

19 Claire E. Turner³

20 Email: <u>c.e.turner@sheffield.a</u>

21 Abdul Karim Sesay¹

22 Email: <u>aksesay@mrc.gm</u>

23 Umberto D'Alessandro¹
- Claire E. Turner 3
- 20 Email: <u>c.e.turner@sheffield.ac.uk</u>
21 Abdul Karim Sesay¹
22 Email: <u>aksesay@mrc.gm</u>
23 Umberto D'Alessandro¹
NOTE: This preprint reports new research tha
- 20
21
22
23 Abdul Karim Sesay $¹$ </sup>
- --
22
23 Email: <u>aksesay@mrc.gm</u>
23 Umberto D'Alessandro¹
NOTE: This preprint reports new
- Umberto D'Alessandro¹

-
- Christian Bottomley²
- 24 Email: <u>udalessandro@mrc.gm</u>

25 Christian Bottomley²

26 Email: <u>christian.bottomley@ls</u>

27 Thushan I. de Silva^{1,3}

28 Email: <u>t.desilva@sheffield.ac.</u>

29 Anna Roca^{1*} 26
27
28
29
30 26 Email: <u>christian.bottomley@lshtm.ac.uk</u>
27 Thushan I. de Silva^{1,3}
28 Email: <u>t.desilva@sheffield.ac.uk</u>
29 Anna Roca^{1*}
30 Email: <u>aroca@mrc.gm</u>
31
- Thushan I. de Silva 1,3
- 28 29 30 31 32 32
- Anna Roca 1^*
- 30
 31
 32
 33
 34 30 Email: <u>aroca@mrc.gm</u>
31
32 **Affiliations:**
¹ Medical Research Co
34 Medicine, Banjul, The
² Faculty of Infectious
-

- 28 Email: <u>t.desilva@sheffield.ac.uk</u>
29 Anna Roca^{1*}
30 Email: <u>aroca@mrc.gm</u>
31 **Affiliations:**
¹ Medical Research Council Unit ¹ Medical Research Council Unit the Gambia at the London School of Hygiene and Tropical
-
- ¹ Medicine, Banjul, The Gambia

34 Medicine, Banjul, The Gambia

² Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicin

³ London, UK

³ The Florey Institute, University of Sheff ² Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine,
- 32
33
34
35
36
37 32 **Affiliations:**
33 ¹ Medical Res
34 Medicine, Ba
35 ² Faculty of Ir
35 London, UK
37 ³ The Florey 1
- ³ The Florey Institute, University of Sheffield, Sheffield, UK.
-
- 34 Medicine, Banjul, The Gambia
35 ² Faculty of Infectious and Trop
36 London, UK
³ The Florey Institute, Universit
38 ***Corresponding Author:** Dise ² Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine,

³ The Florey Institute, University of Sheffield, Sheffield, UK.

³ The Florey Institute, University of Sheffield, Sheffiel 36 London, UK
37 ³ The Florey 1
38 ***Correspond**
40 the LSHTM,
41 **Short Title:** ³ The Florey Institute, University of Sheffield, Sheffield, UK.

38
 ³ Corresponding Author: Disease Control and Elimination T
 40 the LSHTM, The Gambia
 31 Short Title: Intra-partum azithromycin impact on GA 39
40
41
43
43 ***Corresponding Author:** Disease Control and Elimination Theme, MRC Unit The Gambia at

40 the LSHTM, The Gambia

41 **Short Title:** Intra-partum azithromycin impact on GAS

42 **Short Summary**

61 Graphysics (GAS) is an imp
- the LSHTM, The Gambia

41 **Short Title:** Intra-partum

5**hort Summary**

43 Group A streptococcus (G.

44 azithromycin reduced mate

45 *Streptococcus dysgalactia*
-

- **Short Title:** Intra-partum azithromycin impact on GAS
 Short Summary

Group A streptococcus (GAS) is an important cause of s

azithromycin reduced maternal and neonatal GAS carria
 Streptococcus dysgalactiae subspecie 42 **Short Summary**
43 Group A streptoco
44 azithromycin redu
45 *Streptococcus dys*
46 was detected in w
47 43 Group A streptococcus (GAS) is an important cause of sepsis. One oral dose (2g) of intra-partum
44 azithromycin reduced maternal and neonatal GAS carriage. However, azithromycin-resistant
45 Streptococcus dysgalactiae s
-
- 44 azithromycin reduced maternal and neonatal GAS carriage. However, azithromycin-resistant
45 Streptococcus dysgalactiae subspecies equisimilis expressing Lancefield group A carbohydra
46 was detected in women receiving a 45 *Streptococcus dysgalactiae* subspecies *equisimilis* expressing Lancefield group A carbohydrate

46 was detected in women receiving azithromycin.

47
- was detected in women receiving azithromycin.
47

48 Abstract
49 *Backgrou*
50 maternal a
51 *Methods*:
52 1:1) carrie
azithromy *Background*: Group A *Streptococcus* (GAS) is a major human pathogen and an important cause of
maternal and neonatal sepsis.
151 *Methods*: We performed a posthoc analysis of a double-blind, placebo-controlled randomized-50 maternal and neonatal sepsis.

51 *Methods*: We performed a position

52 1:1) carried out in The Gambi

53 azithromycin on maternal and

54 were collected at different tim

55 conventional microbiology tec

56 performed *Methods*: We performed a posthoc analysis of a double-blind, placebo-controlled randomized-trial (ratio

1:1) carried out in The Gambia to determine the impact of one oral dose (2g) of intra-partum

azithromycin on matern 1:1) carried out in The Gambia to determine the impact of one oral dose (2g) of intra-partum

253 azithromycin on maternal and neonatal GAS carriage. Breast milk, nasopharyngeal and vagin

254 were collected at different t azithromycin on maternal and neonatal GAS carriage. Breast milk, nasopharyngeal and vaginal swabs
server collected at different time points during 4 weeks post-treatment. All samples were processed usin
conventional micro were collected at different time points during 4 weeks post-treatment. All samples were processed using
conventional microbiology techniques. Whole genome sequencing (WGS) of GAS isolates was
performed by Illumina MiSeq pl 55 conventional microbiology techniques. Whole genome sequencing (WGS) of GAS isolates was
56 performed by Illumina MiSeq platform.
57 **Results:** We randomized 829 mothers who delivered 843 babies. GAS carriage in mothers 56 performed by Illumina MiSeq platform.

57 **Results:** We randomized 829 mothers w.

38 azithromycin arm was lower in breast m

59 0.90) and the nasopharynx (0.28% vs 1.9

36 (1.99% vs 1.93%, PR=1.03, 95% CI 0.3

51 sligh **Results:** We randomized 829 mothers who delivered 843 babies. GAS carriage in mothers in the azithromycin arm was lower in breast milk (0.28% vs 2.48%, Prevalence Ratio (PR)=0.11, 95% 0.90) and the nasopharynx (0.28% vs 1 azithromycin arm was lower in breast milk (0.28% vs 2.48%, Prevalence Ratio (PR)=0.11, 95% CI 0.01-
0.90) and the nasopharynx (0.28% vs 1.93%, PR=0.15, 95% CI 0.02-1.19), but not in the vaginal tract
(1.99% vs 1.93%, PR=1 69 0.90) and the nasopharynx (0.28% vs 1.93%, PR=0.15, 95% CI 0.02-1.19), but not in the vaginal tract

60 (1.99% vs 1.93%, PR=1.03, 95% CI 0.37-2.91). Among neonates, GAS carriage in the nasopharynx w.

61 slightly lower 60 (1.99% vs 1.93%, PR=1.03, 95% CI 0.37-2.91). Among neonates, GAS carriage in the nasopharynx was

61 slightly lower in the azithromycin arm (0.57% vs 1.91%, PR=0.30, 95% CI 0.06-1.42). Prevalence of

62 azithromycin-re 61 slightly lower in the azithromycin arm (0.57% vs 1.91%, PR=0.30, 95% CI 0.06-1.42). Prevalence of
62 azithromycin-resistant GAS was similar in both arms, except for a higher prevalence in the vaginal tra
63 among women 62 azithromycin-resistant GAS was similar in both arms, except for a higher prevalence in the vaginal tract
63 among women in the azithromycin arm (1.99% vs 0.28%, PR=7.24, 95% CI 0.87-56.92). WGS revealed
64 ten of the 4 among women in the azithromycin arm (1.99% vs 0.28%, PR=7.24, 95% CI 0.87-56.92). WGS revealed
ten of the 45 GAS isolates (22.2%) were *Streptococcus dysgalactiae* subspecies *equisimilis* expressing
Lancefield group A ca 64 ten of the 45 GAS isolates (22.2%) were *Streptococcus dysgalactiae* subspecies *equisimilis* expressing

65 Lancefield group A carbohydrate (SDSE(A)). All SDSE(A) isolates were azithromycin-resistant,

66 harbouring ma

Example 165 Lancefield group A carbohydrate (SDSE(A)). All SDSE(A) isolates were azithromycin-resistant,

harbouring macrolide resistant genes *msrD* and *mefA*.
 Conclusions: Oral intra-partum azithromycin reduced prev harbouring macrolide resistant genes *msrD* and *mefA*.
 Conclusions: Oral intra-partum azithromycin reduced

neonates. Azithromycin-resistant SDSE(A) carriage w

azithromycin.
 Trial registration: ClinicalTrials.gov I 67 **Conclusions**: Oral intra-partum azithromycin reduced prevalence of GAS carriage among mothers and
neonates. Azithromycin-resistant SDSE(A) carriage was observed among participants treated with
azithromycin.
Trial regis neonates. Azithromycin-resistant SDSE(A) carriage was observed among participants treated with
azithromycin.
Trial registration: ClinicalTrials.gov Identifier NCT01800942
3 69 azithromycin.
70 **Trial registra**

70 **Trial registration:** ClinicalTrials.gov Identifier NCT01800942

- 71 **Keywords:** Sub-Saharan Africa, azithromycin, bacterial carriage, group A *streptococcus*, *Streptococcus*
- 72 *dysgalactiae subspecies equisimilis*

74 BACKGROUND
75 Pregnant women at
76 19% of maternal de
77 mortality due to ma
78 significant cause of
79 *Staphylococcus au:*
80 sepsis [5-7]. Group Pregnant women and neonates are at highest risk of sepsis, up to 6 weeks after delivery, resulting in 6-

19% of maternal deaths [1, 2]. Low- and middle-income countries (LMICs) have the highest burden of

mortality due to 19% of maternal deaths [1, 2]. Low- and middle-income countries (LMICs) have the highest burden of
1711 mortality due to maternal sepsis, with the highest rates in sub-Saharan Africa (SSA). Neonatal sepsis is
1781 signific mortality due to maternal sepsis, with the highest rates in sub-Saharan Africa (SSA). Neonatal sepsis is a significant cause of severe morbidity and is estimated to cause 7% of under-5 mortality [3, 4]. Globally, *Staphylo* 51 significant cause of severe morbidity and is estimated to cause 7% of under-5 mortality [3, 4]. Globally,

51 Staphylococcus aureus and Group B Streptococcus (GBS) are main causes of maternal and neonatal

82 sepsis [5-*Staphylococcus aureus* and Group B *Streptococcus* (GBS) are main causes of maternal and neonatal

sepsis [5-7]. Group A *Streptococcus* (GAS; *Streptococcus pyogenes*) is increasingly recognized as ar

important Gram-pos sepsis [5-7]. Group A *Streptococcus* (GAS; *Streptococcus pyogenes*) is increasingly recognized as an

81 important Gram-positive pathogen associated with maternal and neonatal sepsis [8-10]. GAS can caus

82 both early a 81 important Gram-positive pathogen associated with maternal and neonatal sepsis [8-10]. GAS can cause
82 both early and late onset of neonatal sepsis [11, 12], usually as a result of infection acquired through the
81 birt both early and late onset of neonatal sepsis [11, 12], usually as a result of infection acquired through the

birth canal [12].

84 Surveillance conducted in the USA between 1995 and 2000 estimated an annual incidence of 6 83 birth canal [12].
84 Surveillance con
85 100,000 live birt
86 [13]. A review o
87 [14]. Between 20
88 was 1.5 per 100, 84 Surveillance conducted in the USA between 1995 and 2000 estimated an annual incidence of 6 per
85 100,000 live births of GAS-related maternal sepsis, with a 3.5% case-fatality ratio in invasive disea
86 [13]. A review o 100,000 live births of GAS-related maternal sepsis, with a 3.5% case-fatality ratio in invasive disease

113]. A review of pregnancy-related GAS infections between 1974 and 2009 included no data from SS

114]. Between 2010 113]. A review of pregnancy-related GAS infections between 1974 and 2009 included no data from SSA

114]. Between 2010 and 2016, the incidence of GAS neonatal sepsis in London and the south of England

114]. Between 2010 a 14]. Between 2010 and 2016, the incidence of GAS neonatal sepsis in London and the south of England

188 was 1.5 per 100,000 person years [15]. There is limited data on the burden of GAS infections in SSA due

189 to the l was 1.5 per 100,000 person years [15]. There is limited data on the burden of GAS infections in SSA due
to the lack of systematic surveillance [16]. In the Eastern Cape, South Africa, the mean annual incidence
rate of inva 89 to the lack of systematic surveillance [16]. In the Eastern Cape, South Africa, the mean annual incidence

80 rate of invasive GAS infection was 6 cases per 100,000-person years in all age groups (58% of samples

81 fro 90 rate of invasive GAS infection was 6 cases per 100,000-person years in all age groups (58% of samples

91 from 18-64 year olds) [17]. In Kenya, the incidence of neonatal GAS sepsis was 0.6 cases per 1,000 live

92 birth 91 from 18-64 year olds) [17]. In Kenya, the incidence of neonatal GAS sepsis was 0.6 cases per 1,000 live

92 births [18]. GAS also causes non-invasive disease, including tonsillo-pharyngitis, skin infections and

93 rheu births [18]. GAS also causes non-invasive disease, including tonsillo-pharyngitis, skin infections and

93 rheumatic fever that can result in rheumatic heart disease [17, 19, 20].

94 We conducted a double-blind randomized 93 rheumatic fever that can result in rheumatic heart disease [17, 19, 20].
94 We conducted a double-blind randomized trial (the PregnAnZI trial) to
95 intra-partum azithromycin in reducing bacterial carriage of the main G 94 We conducted a double-blind randomized trial (the PregnAnZI trial) to assess the effect of 2g of oral

95 intra-partum azithromycin in reducing bacterial carriage of the main Gram-positive pathogens associa

96 with neo 95 intra-partum azithromycin in reducing bacterial carriage of the main Gram-positive pathogens associated
96 with neonatal sepsis (*S. aureus, Streptococcus pneumoniae* and GBS) in the mother and the newborn
97 during the 96 with neonatal sepsis (*S. aureus*, *Streptococcus pneumoniae* and GBS) in the mother and the newborn
97 during the 4 weeks following the intervention [21]. The trial showed a consistent reduction of bacteri
97 97 during the 4 weeks following the intervention [21]. The trial showed a consistent reduction of bacterial 5

-
-
-
-
- examples of these three bacteria in both the mother and their newborns during the entire neonatal period
and a decrease in the occurrence of disease [22, 23]. We present here a posthoc analysis of the trial to
determine th 99 and a decrease in the occurrence of disease [22, 23]. We present here a posthoc analysis of the trial to

00 determine the effect of 2g intra-partum azithromycin on the prevalence and antibiotic resistance of GA

in m 100 determine the effect of 2g intra-partum azithromycin on the prevalence and antibiotic resistance of GAS
101 in mothers and their newborns during the 4 weeks following the intervention. We also used whole
102 genome seq 101 in mothers and their newborns during the 4 weeks following the intervention. We also used whole genome sequencing (WGS) to further characterise the GAS isolates and perform phylogenetic anal genome sequencing (WGS) to 102 genome sequencing (WGS) to further characterise the GAS isolates and perform phylogenetic analysis.

Equation 102 set of the GAS isolates and perform phylogenetic analysis.

The GAS isolates and perform phylogenetic an

-
-
- 103 **METHODS**
104 **Study Desigr**
105 This study is
106 women in lab
107 (ratio 1:1) [2]
108 health facility **Study Design/Population**

105 This study is a posthoc ana

106 women in labour were rand

107 (ratio 1:1) [21]. The trial w

108 health facility located in we

109 population in the catchmen

110 Between April 2013 and A
-
- This study is a posthoc analysis of data from a double-blind, placebo-controlled randomized trial in which

106 women in labour were randomized to receive either a single dose of 2g of oral azithromycin or placebo

107 (ra women in labour were randomized to receive either a single dose of 2g of oral azithromycin or placebo

(ratio 1:1) [21]. The trial was conducted at the Jammeh Foundation for Peace (JFP), a government-run

health facility l (ratio 1:1) [21]. The trial was conducted at the Jammeh Foundation for Peace (JFP), a government-run

108 health facility located in western Gambia that manages approximately 4,500 deliveries per year. The

109 population health facility located in western Gambia that manages approximately 4,500 deliveries per year. The
109 population in the catchment area is representative of The Gambia and covers its main ethnic groups [
110 Between April 109 population in the catchment area is representative of The Gambia and covers its main ethnic groups [22].

110 Between April 2013 and April 2014, women aged 18-45 years attending the JFP labour ward and with no

111 acu
-
- 110 Between April 2013 and April 2014, women aged 18-45 years attending the JFP labour ward and with no

111 acute or chronic conditions were recruited into the trial. Details of exclusion criteria have been reported

112 211 acute or chronic conditions were recruited into the trial. Details of exclusion criteria have been reported

212 elsewhere [21]. The women had provided written informed consent to participate in the study during

213 p
-
-
-

elsewhere [21]. The women had provided written informed consent to participate in the study during
113 previous antenatal care visits. Women and their newborns were followed for up to 8 weeks postpartur
114 and biological 113 previous antenatal care visits. Women and their newborns were followed for up to 8 weeks postpartum

114 and biological samples were collected during the first 4 weeks [21, 22].

115 **Study Samples**

115 A nasopharynge and biological samples were collected during the first 4 weeks [21, 22].
 Study Samples
 A nasopharyngeal swab (NPS) and a low vaginal swab (VS) were collec

intervention was administered and during labour. Post-interv **Study Samples**

116 A nasopharynge

117 intervention was

118 within 6 h after l

119 and newborns, a

120 the postnatal che 116 A nasopharyngeal swab (NPS) and a low vaginal swab (VS) were collected from women before the intervention was administered and during labour. Post-intervention samples included: (i) newborn N within 6 h after birth; (i 117 intervention was administered and during labour. Post-intervention samples included: (i) newborn NPS
118 within 6 h after birth; (ii) samples collected during home visits at days 3, 6, 14 and 28 (NPS from mothe
119 and

118 within 6 h after birth; (ii) samples collected during home visits at days 3, 6, 14 and 28 (NPS from mothers

219 and newborns, and breast milk(BM) from mothers) and (iii) a VS collected in the health facility during

2 119 and newborns, and breast milk(BM) from mothers) and (iii) a VS collected in the health facility during
120 the postnatal check at day 8-10 post-delivery [22].
121

120 the postnatal check at day 8-10 post-delivery [22].
121

-
-
- 123 NPS were collected by passing the tip of a calcium alginate (Expotech USA Inc) swab across the mucosa
124 of the posterior wall of the nasopharynx. The swab was rotated and left in the nasopharynx for
125 approximately approximately 5 seconds. The inoculated swab was placed immediately into a vial containing skim milk-
tryptone-glucose-glycerol (STGG) transport medium and then into a cold box before being taken to the
Medicial Research C
-
- **Sample collection**

123 NPS were collecte

124 of the posterior wal

125 approximately 5 see

126 tryptone-glucose-gl

127 Medical Research (

128 Medicine (LSHTM
-
- 124 of the posterior wall of the nasopharynx. The swab was rotated and left in the nasopharynx for

125 approximately 5 seconds. The inoculated swab was placed immediately into a vial containing s

126 tryptone-glucose-gly tryptone-glucose-glycerol (STGG) transport medium and then into a cold box before being taken to the
127 Medical Research Council Unit The Gambia (MRC) at the London School of Hygiene and Tropical
128 Medicine (LSHTM) labo Medical Research Council Unit The Gambia (MRC) at the London School of Hygiene and Tropical

128 Medicine (LSHTM) laboratories within 8 hours of collection [21].

129 VS were collected by inserting a sterile cotton swab (S Medicine (LSHTM) laboratories within 8 hours of collection [21].
129 VS were collected by inserting a sterile cotton swab (Sterilin Ltd, I
130 rotating the swab with a circular motion, leaving it in the vagina fo
131 inocu VS were collected by inserting a sterile cotton swab (Sterilin Ltd, UK) 2–3 cm into the vagina and

130 rotating the swab with a circular motion, leaving it in the vagina for approximately 5 seconds. The

131 inoculated sw
-
- rotating the swab with a circular motion, leaving it in the vagina for approximately 5 seconds. The

131 inoculated swabs were then placed immediately into the vials containing STGG and put in a cold b

132 before being tr
-
- imoculated swabs were then placed immediately into the vials containing STGG and put in a cold box

132 before being transferred to the MRC laboratories within 8 hours [21].

133 Breast milk samples were collected by first before being transferred to the MRC laboratories within 8 hours [21].

133 Breast milk samples were collected by first disinfecting the nipple and

134 cotton soaked with 0.02 % chlorhexidine. Mothers were then asked to

1
-
- 133 Breast milk samples were collected by first disinfecting the nipple and areola of the breast using sterile

134 cotton soaked with 0.02 % chlorhexidine. Mothers were then asked to manually express their milk. The

135 cotton soaked with 0.02 % chlorhexidine. Mothers were then asked to manually express their milk. The

first 0.5 mL was discarded. The following 1-2 mL was collected in a sterile plastic bijoux bottle put in a

cold box and
-

-
- first 0.5 mL was discarded. The following 1-2 mL was collected in a sterile plastic bijoux bottle put in a
cold box and transferred to the MRC laboratories within 8 hours [21].
Laboratory Procedures
GAS culture from NPS
- cold box and transferred to the MRC laboratories within 8 hours [21].
 137 Laboratory Procedures
 138 GAS culture from NPS, VS and breast milk samples
 139 Samples were vortexed for 20 seconds prior to storage a **Laboratory Procedures**

138 *GAS culture from NPS***, 1

139 Samples were vortexed fc

140 During processing, sampl

141 homogenise the medium a

142 UK +0.02 % crystal viole** GAS culture from NPS, VS and breast milk samples

Samples were vortexed for 20 seconds prior to storage

During processing, samples were allowed to thaw on i

homogenise the medium and 50µl was dispensed onto

UK +0.02 % c Samples were vortexed for 20 seconds prior to storage at −70°C for subsequent processing in batches.

140 During processing, samples were allowed to thaw on ice. Each vial was then vortexed briefly in order thomogenise t During processing, samples were allowed to thaw on ice. Each vial was then vortexed briefly in order to

141 homogenise the medium and 50µl was dispensed onto crystal violet blood agar (CVBA) (CM0085 Oxoio

142 UK +0.02 % 141 homogenise the medium and 50μl was dispensed onto crystal violet blood agar (CVBA) (CM0085 Oxoid,

142 UK +0.02 % crystal violet) for selective isolation of beta-haemolytic streptococci [21].

143 After 20–24 h incuba
-
- 143 After 20–24 h incubation, presumptive beta-haemolytic colonies were streaked onto blood agar to obtain
144 a pure growth. A catalase test was performed to differentiate the presumptive streptococci from
8
- UK +0.02 % crystal violet) for selective isolation of beta-haemolytic streptococci [21].

143 After 20–24 h incubation, presumptive beta-haemolytic colonies were streaked onto blom

144 a pure growth. A catalase test was p 144 a pure growth. A catalase test was performed to differentiate the presumptive streptococci from

- 146 kit (Remel R30950501) and ultimately reported as group A, B, C, D, F or G [21].

147 Antimicrobial Susceptibility Testing

148 Pure morphologically similar colonies were made into a suspension equal to 0.5%

149 and s Antimicrobial Susceptibility Testing
148 Pure morphologically similar colonies
149 and streaked evenly over the surface of
150 evaluated using the disk diffusion me
151 inhibition \leq 13mm) were confirmed us
152 CLSI 2016 148 Pure morphologically similar colonies were made into a suspension equal to 0.5% MacFarland's standard

149 and streaked evenly over the surface of Muller Hinton Agar (MHA). Antimicrobial resistance was

150 evaluated
-
- and streaked evenly over the surface of Muller Hinton Agar (MHA). Antimicrobial resistance was

evaluated using the disk diffusion method (15 ug azithromycin disk) and all resistant isolates(zones

inhibition \leq 13mm) w
-
-

- evaluated using the disk diffusion method (15 ug azithromycin disk) and all resistant isolates(zones of

inhibition \leq 13mm) were confirmed using E-test (AZ 256, range 0.016-256ug/ml, Biomerieux) [21]. Th

CLSI 2016 guid 151 inhibition ≤13mm) were confirmed using E-test (AZ 256,range 0.016-256ug/ml, Biomerieux) [21]. The

152 CLSI 2016 guidelines were used to interpret azithromycin susceptibility results.

153 Whole genome sequencing

15 CLSI 2016 guidelines were used to interpret azithromycin susceptibility results.

Whole genome sequencing

153 Whole genome sequencing

154 Extracted DNA from all GAS isolates (isolated at any timepoint) was used for W

15 Whole genome sequencing
154 Extracted DNA from all GA
155 Paired end reads quality che
156 (Trimmomatic), followed by
157 25]. Assembled genomes we
158 further analysis were <500 c
159 subspecies *equisimilis*: SDS
-
-
-
-
-
- Extracted DNA from all GAS isolates (isolated at any timepoint) was used for WGS by Illumina Miseq.

155 Paired end reads quality checked (FastQC) and trimmed for adaptor contaminant and low Q-score bases

156 (Trimmomatic Paired end reads quality checked (FastQC) and trimmed for adaptor contaminant and low Q-score bases

156 (Trimmomatic), followed by *de novo* assembly using k-mer settings of 21, 22, 55 and 77 (SPAdes) [24,

157 25]. Assem 156 (Trimmomatic), followed by *de novo* assembly using k-mer settings of 21, 22, 55 and 77 (SPAdes) [24, 25]. Assembled genomes were checked for post-assembly quality (QUAST) [26]. Criteria for inclusion in further analys 25]. Assembled genomes were checked for post-assembly quality (QUAST) [26]. Criteria for inclusion in further analysis were <500 contigs, 1.6-2.0Mb (*S. pyogenes*) or 2.0-2.4Mb (*Streptococcus dysgalactiae* subspecies *equ* further analysis were <500 contigs, 1.6-2.0Mb (*S. pyogenes*) or 2.0-2.4Mb (*Streptococcus dysgalactiae* subspecies *equisimilis*; SDSE) assembly length, and >90% reference genome coverage (*S. pyogenes*). Assembled genome subspecies *equisimilis*; SDSE) assembly length, and >90% reference genome coverage (*S. pyogenes*).
160 Assembled genomes were annotated using Prokka and the core genome determined using Roary [27,2
161 Antimicrobial resi Assembled genomes were annotated using Prokka and the core genome determined using Roary [27,28].

161 Antimicrobial resistance genes were identified using ABRicate with the Resfinder database [29.30].

162 Emm-typing was
-
-
-
-
-
- Antimicrobial resistance genes were identified using ABRicate with the Resfinder database [29.30].

162 Emm-typing was performed using the bioinformatics method described at

163 https://github.com/BenlamesMetcalf and the *Emm*-typing was performed using the bioinformatics method described at

<u>https://github.com/BenlamesMetcalf</u> and the CDC *emm*-typing database

(https://www2.cdc.gov/vaccines/biotech/strepblast.asp). Core genome a

maximu https://github.com/BenJamesMetcalf and the CDC *emm*-typing database

(https://www2.cdc.gov/vaccines/biotech/strepblast.asp). Core genome a

maximum likelihood phylogenetic trees (RAxML) with 1000 bootstraps [3

phylogenet (https://www2.cdc.gov/vaccines/biotech/strepblast.asp). Core genome alignments were used to draw

maximum likelihood phylogenetic trees (RAxML) with 1000 bootstraps [31]. For comparative

phylogenetic analysis of SDSE isol maximum likelihood phylogenetic trees (RAxML) with 1000 bootstraps [31]. For comparative

166 phylogenetic analysis of SDSE isolates, complete genomes were obtained from NCBI Genome

167 (https://ncbi.nlm.nih.gov/genome/ge phylogenetic analysis of SDSE isolates, complete genomes were obtained from NCBI Genome resource

167 (https://ncbi.nlm.nih.gov/genome/genomes/823?) and from a previous study reporting SDSE expressing

168 Lancefield group
- 167 (https://ncbi.nlm.nih.gov/genome/genomes/823?) and from a previous study reporting SDSE expressing
168 Lancefield group A (SDSE(A)) [32]. Phylogenetic trees were visualized using iTOL
9
- 168 Lancefield group A (SDSE(A)) [32]. Phylogenetic trees were visualized using iTOL 9

-
-
- (https://itol.embl.de/). All sequence data are publicly available at the European Nucleotide Archive
170 (project accession PRJEB36490).
171 **Data Management and Statistical Analysis**
172 The data was double entered into O (project accession PRJEB36490).

171 **Data Management and Statistic:**

172 The data was double entered into the participants with all samples colle

174 carriage was determined as the pre

175 compared between arms using p **Data Management and Statistical Analysis**
172 The data was double entered into Open Clinic
173 participants with all samples collected at each
174 carriage was determined as the presence at an
175 compared between arms us The data was double entered into Open Clinica and analysed using STATA 16. We only included
173 participants with all samples collected at each of the specified timepoints. The prevalence of GAS
174 carriage was determined participants with all samples collected at each of the specified timepoints. The prevalence of GAS

carriage was determined as the presence at any time point for each of the sample types. Prevalence

compared between arms
- 174 carriage was determined as the presence at any time point for each of the sample types. Prevalence was

175 compared between arms using prevalence ratios (PR) with their corresponding 95% confidence interval

176 (CI).
- 176 (CI). We used Fisher exact test to obtain p-values. Prevalence of azithromycin resistance was calculated
177 considering all sampled individuals as the denominator. If any isolate from a biological site was resistant
1
- compared between arms using prevalence ratios (PR) with their corresponding 95% confidence intervals
176 (CI). We used Fisher exact test to obtain p-values. Prevalence of azithromycin resistance was calculated
177 consider 177 considering all sampled individuals as the denominator. If any isolate from a biological site was resistant,
178 the sample of that participant was considered as resistant.
179 Ethical Approval
180 Ethical approval for
- the sample of that participant was considered as resistant.

179 Ethical Approval

180 Ethical approval for the main trial was obtained from the J

181 Committee. Ethical approval was given by LSHTM for the

182

- 179 **Ethical Approval**
180 Ethical approval fo
181 Committee. Ethical
182 **RESULTS** 180 Ethical approval for the main trial was obtained from the Joint MRC Gambia Government Ethics
181 Committee. Ethical approval was given by LSHTM for the secondary data analysis.
182 RESULTS
184 Study Population
-

181 Committee. Ethical approval was given by LSHTM for the secondary data analysis.

182 RESULTS

184 Study Population

185 We recruited 829 women for the trial (414 women to the azithromycin and 415 to the 185 Library of ---
183
184
185
186
187 185 We recruited 829 women for the trial (414 women to the azithromycin and 415 to the placebo arms) who delivered a total of 843 babies, including 13 stillbirths. Overall, 715 pairs (86.2%) had all study samples collected

-
- **RESULTS**
 184 Study Popu
 185 We recruite
 **186 delivered a 1

187** collected an
 188 major ethnic 184 **Study Population**
185 We recruited 829 w
186 delivered a total of
187 collected and are pa
188 major ethnic group
189 (November to May
190 (Table 1). delivered a total of 843 babies, including 13 stillbirths. Overall, 715 pairs (86.2%) had all study samples

collected and are part of this posthoc analysis (Figure 1). Most women were 20-29 years old and the

major ethnic collected and are part of this posthoc analysis (Figure 1). Most women were 20-29 years old and the

188 major ethnic group was Mandinka. Approximately 66.6% of deliveries occurred during the dry seaso

189 (November to Ma 188 major ethnic group was Mandinka. Approximately 66.6% of deliveries occurred during the dry season (November to May), 5.0% of the newborns were low-birth weight and slightly more than half were ma (Table 1).

10

189 (November to May), 5.0% of the newborns were low-birth weight and slightly more than half were males

(Table 1).

10

190 (Table 1).

-
-
- 192 Overall, 30 women and 9 newborns had at least 1 sample positive for GAS; 7 women and one baby had 2 positive samples and one woman had 5 positive samples (Total of 51 GAS isolates).

193 *Study mothers*. Pre-intervent
-
- **Prevalence of GAS carriage**

192 Overall, 30 women and 9 new

193 positive samples and one wom

194 Study mothers. Pre-interventio

195 nasopharynx and in the vagina

196 azithromycin arm was lower in 193 positive samples and one woman had 5 positive samples (Total of 51 GAS isolates).

194 *Study mothers*. Pre-intervention prevalence of GAS was low and similar in the two s

195 nasopharynx and in the vaginal tract (Ta
- 196 azithromycin arm was lower in the nasopharynx (0.28% versus 1.93%, PR=0.15 95% CI (0.02,1.19),

197 p=0.069) and breast milk (0.28% versus 2.48%, PR=0.11 95% CI (0.01,0.90), p=0.021) but not in the

198 vaginal tract
-
- *Study mothers*. Pre-intervention prevalence of GAS was low and similar in the two study arms, both in the nasopharynx and in the vaginal tract (Table 2, Figure 2a). Post intervention, prevalence of GAS in the azithromycin nasopharynx and in the vaginal tract (Table 2, Figure 2a). Post intervention, prevalence of GAS in the

azithromycin arm was lower in the nasopharynx (0.28% versus 1.93%, PR=0.15 95% CI (0.02,1.19),

p=0.069) and breast m 197 p=0.069) and breast milk (0.28% versus 2.48%, PR=0.11 95% CI (0.01,0.90), p=0.021) but not in the

198 vaginal tract (1.99% versus 1.93%, PR=1.03 95%CI (0.37,2.91), p=1.000) (Table 2).

199 *Study newborns*. Prevalenc vaginal tract (1.99% versus 1.93%, PR=1.03 95%CI (0.37,2.91), p=1.000) (Table 2).

199 *Study newborns*. Prevalence of nasopharyngeal carriage of GAS was low; with a lowe

200 azithromycin arm (0.57% versus 1.91%, PR=0.30 *Study newborns*. Prevalence of nasopharyngeal carriage of GAS was low; with a lower prevalence in the azithromycin arm (0.57% versus 1.91%, PR=0.30 95%CI (0.06,1.42), p=0.178) (Table 2, Figure 2b).
 Prevalence of azithro
- 200 azithromycin arm (0.57% versus 1.91%, PR=0.30 95%CI (0.06,1.42), p=0.178) (Table 2, Figure 2b).

201 **Prevalence of azithromycin resistance**

202 *Study mothers*. Prevalence of azithromycin-resistant GAS was similar be

-
-

Prevalence of azithromycin resistance
202 *Study mothers*. Prevalence of azithromyc
203 types except for higher resistance in vag
204 PR=7.24, 95% CI (0.87,56.92 p=0.035)]
205 *Study newborns*. Prevalence of GAS azit
206 202 *Study mothers*. Prevalence of azithromycin-resistant GAS was similar between study arms for all sample
203 types except for higher resistance in vaginal GAS isolates in the intervention arm [1.99% vs. 0.28%,
204 PR=7. types except for higher resistance in vaginal GAS isolates in the intervention arm [1.99% vs. 0.28%,

204 PR=7.24, 95% CI (0.87,56.92 p=0.035)] (Table 3).

205 *Study newborns*. Prevalence of GAS azithromycin resistance wa 204 PR=7.24, 95% CI (0.87,56.92 p=0.035)] (Table 3).

205 *Study newborns*. Prevalence of GAS azithromycin r

206 two participants having resistant GAS isolates (Tab

207 **Whole Genome Sequencing**

208 Of the 51 GAS isola 205 *Study newborns*. Prevalence of GAS azithromycin resistance was low and similar between arms with only
206 two participants having resistant GAS isolates (Table 3).
207 **Whole Genome Sequencing**
208 Of the 51 GAS isola two participants having resistant GAS isolates (Table 3).

207 **Whole Genome Sequencing**

208 Of the 51 GAS isolates, one sample was not retrieved and

209 poor sequences and were excluded from the WGS analysi

210 that 35

-
- **207 Whole Genome Sequencing**

208 Of the 51 GAS isolates, one s:

209 poor sequences and were excl

210 that 35 were *S. pyogenes* (2 fr

211 which we detected 16 *emm* ty₁

212 *emm*147 (4 isolates, 11.4%). 208 Of the 51 GAS isolates, one sample was not retrieved and five samples (isolated from four mothers) had

209 poor sequences and were excluded from the WGS analysis. Of the remaining 45 isolates, WGS confirme

210 that 3 209 poor sequences and were excluded from the WGS analysis. Of the remaining 45 isolates, WGS confirmed

210 that 35 were *S. pyogenes* (2 from the azithromycin arm and 33 from the placebo arm of the trial), from

211 whi 210 that 35 were *S. pyogenes* (2 from the azithromycin arm and 33 from the placebo arm of the trial), from
211 which we detected 16 *emm* types. The most common were *emm*4 and *emm*44 (5 isolates each, 14.2%) *emm*147 (4
- 211 which we detected 16 *emm* types. The most common were *emm*4 and *emm*44 (5 isolates each, 14.2%) and *emm*147 (4 isolates, 11.4%). The remaining 10 isolates were SDSE. All were phenotypically resistant to 11
- 212 *emm*147 (4 isolates, 11.4%). The remaining 10 isolates were SDSE. All were phenotypically resistant to 11

227 linked to those recovered from the baby's mother (Figure 3b).
228 **DISCUSSION**
230 One oral dose (2g) of azithromycin given to women in labour 1
231 among women and their babies in the nasopharynx and breast :
232 resi 229
230
231
232
233 229 **DISCUSSION**
230 One oral dose (2
231 among women a
232 resistance in iso
233 prevalence of G
234 azithromycin-re One oral dose (2g) of azithromycin given to women in labour reduced the prevalence of GAS carriage

231 among women and their babies in the nasopharynx and breast milk without an increase of azithromycir

232 resistance in among women and their babies in the nasopharynx and breast milk without an increase of azithromycin

resistance in isolates in these sample sites. In contrast, the intervention did not have any effect on the

prevalence of resistance in isolates in these sample sites. In contrast, the intervention did not have any effect on the prevalence of GAS carriage in the vaginal tract but induced an increase in the carriage prevalence of azithromycin-

prevalence of GAS carriage in the vaginal tract but induced an increase in the carriage prevalence of azithromycin-resistant SDSE(A).

235 We have previously shown that a single oral dose (2g) of azithromycin given to wome 234 azithromycin-resistant SDSE(A).
235 We have previously shown that a
236 the prevalence of *S. aureus*, *S. pno* 235 We have previously shown that a single oral dose (2g) of azithromycin given to women in labour reduced
236 the prevalence of *S. aureus, S. pneumoniae* and GBS carriage in the mother (nasopharynx, breast milk and
 12 236 the prevalence of *S. aureus, S. pneumoniae* and GBS carriage in the mother (nasopharynx, breast milk and 12

vaginal tract) and the baby (nasopharynx) [22]. The current analysis shows that the intervention also

reduced the prevalence of GAS carriage in the breast milk and nasopharynx of study women and, les

clearly, in the naso

reduced the prevalence of GAS carriage in the breast milk and nasopharynx of study women and, less

239 clearly, in the nasopharynx of their newborns. Despite substantial reduction of GAS carriage, we did n

240 observe an clearly, in the nasopharynx of their newborns. Despite substantial reduction of GAS carriage, we did not

240 observe any short-term increase of azithromycin resistance in these two biological sites.

241 Conversely, the i observe any short-term increase of azithromycin resistance in these two biological sites.

241 Conversely, the intervention did not have any effect on the prevalence of GAS carriage i

242 vaginal tract but induced an incr 241 Conversely, the intervention did not have any effect on the prevalence of GAS carriage in the maternal
242 vaginal tract but induced an increase in azithromycin resistance. WGS revealed that GAS vaginal carria
243 in t vaginal tract but induced an increase in azithromycin resistance. WGS revealed that GAS vaginal carriage

243 in the azithromycin arm was primarily due to azithromycin-resistant SDSE(A), whereas in the placebo

244 arm, GA in the azithromycin arm was primarily due to azithromycin-resistant SDSE(A), whereas in the placebo

244 arm, GAS vaginal carriage was entirely due to azithromycin-susceptible *S. pyogenes*. In our previous

245 analysis o 244 arm, GAS vaginal carriage was entirely due to azithromycin-susceptible *S. pyogenes*. In our previous
245 analysis on *S. aureus*, lower reduction in carriage in the vaginal tract alongside a higher prevalence of
246 analysis on *S. aureus*, lower reduction in carriage in the vaginal tract alongside a higher prevalence of resistance was also observed [22]. It is not clear why the effect of the intervention in the vaginal tract differs resistance was also observed [22]. It is not clear why the effect of the intervention in the vaginal tract

247 differs from other body sites. The concentration of azithromycin in the vaginal tract may be lower and

248 m differs from other body sites. The concentration of azithromycin in the vaginal tract may be lower and fall

248 more rapidly than in other biological sites. We had previously shown a very high concentration of

250 azith more rapidly than in other biological sites. We had previously shown a very high concentration of

249 azithromycin in breast milk during the 4 weeks following the intervention, with a peak during the 1

250 days (concent 249 azithromycin in breast milk during the 4 weeks following the intervention, with a peak during the first 6

250 days (concentration >4,000 μ g/L) [33]. A different study using a single dose of azithromycin (1g)

351 days (concentration >4,000 μ g/L) [33]. A different study using a single dose of azithromycin (1g)
251 showed the azithromycin concentration in the vaginal tract was much lower than the breast milk
252 concentration we 251 showed the azithromycin concentration in the vaginal tract was much lower than the breast milk

252 concentration we observed [34]. In this study, the peak concentration occurred during the first 24

253 hours followin concentration we observed [34]. In this study, the peak concentration occurred during the first 24-48
hours following the intervention [34], long before the post-intervention VS were collected in our stud
is possible that hours following the intervention [34], long before the post-intervention VS were collected in our study. It

254 is possible that removal of *S. pyogenes* from the vaginal tract allows azithromycin-resistant SDSE to

255 t 254 is possible that removal of *S. pyogenes* from the vaginal tract allows azithromycin-resistant SDSE to
255 thrive, whereas in other body sites higher concentrations of azithromycin can overcome the efflux-
256 mediated 255 thrive, whereas in other body sites higher concentrations of azithromycin can overcome the efflux-

256 mediated resistance mechanisms [35]. An alternative explanation is that even though SDSE can be

257 in different mediated resistance mechanisms [35]. An alternative explanation is that even though SDSE can be found

in different biological sites, it is better suited to survive in the vaginal tract [36]. One azithromycin-

resistant S 257 in different biological sites, it is better suited to survive in the vaginal tract [36]. One azithromycin-

258 resistant SDSE(A) was isolated in the vaginal tract from a woman included in the azithromycin arm

259 bef 258 resistant SDSE(A) was isolated in the vaginal tract from a woman included in the azithromycin arm
259 before the intervention was administered. A phylogenetically-linked isolate was isolated from the sa
260 woman's VS 259 before the intervention was administered. A phylogenetically-linked isolate was isolated from the same
woman's VS after the intervention.
13 260 woman's VS after the intervention.

261 The public health and clinical implications of the selective expansion of SDSE(A) in the vaginal tract are difficult to anticipate. However, similarly to *S. pyogenes*, SDSE can cause invasive disease [37-39]. Lancefi difficult to anticipate. However, similarly to *S. pyogenes*, SDSE can cause invasive disease [37-39].

263 Lancefield group A SDSE has been described in previous studies from high income settings, includi

collection of i 263 Lancefield group A SDSE has been described in previous studies from high income settings, including a collection of isolates causing invasive disease in the USA [32]. The SDSE(A) isolated from our study participants h 264 collection of isolates causing invasive disease in the USA [32]. The SDSE(A) isolated from our study

265 participants have distinct phylogeny to SDSE(A) previously isolated in USA and fall into two distinct

266 clad 265 participants have distinct phylogeny to SDSE(A) previously isolated in USA and fall into two distinct

266 clades. In our study, all SDSE(A) isolates harboured *mefA-msrD* genes, whereas both *erm(B)* and *mef*,

267 clades. In our study, all SDSE(A) isolates harboured *mefA-msrD* genes, whereas both *erm(B)* and *mefA-msrD* genes were found in azithromycin-resistant *S. pyogenes* isolates. While the presence of *mefA* is associated wi *msrD* genes were found in azithromycin-resistant *S. pyogenes* isolates. While the presence of *mefA* is

268 associated with macrolide resistance, *msrD* has a more dominant role [40, 41]. The presence of both *m*

269 a associated with macrolide resistance, *msrD* has a more dominant role [40, 41]. The presence of both *mefA*

269 and *msrD* may confer high level resistance [41].

270 The trial was designed to evaluate the effect of intra 269 and *msrD* may confer high level resistance [41].

270 The trial was designed to evaluate the effect of ir

271 carriage of *S. aureus*, *S. pneumoniae* and GBS th

272 current analysis was underpowered as observed i
 270 The trial was designed to evaluate the effect of intra-partum azithromycin on maternal and neonatal
271 carriage of *S. aureus*, *S. pneumoniae* and GBS that are more prevalent than *S. pyogenes* and therefor
272 curre carriage of *S. aureus*, *S. pneumoniae* and GBS that are more prevalent than *S. pyogenes* and therefore the

current analysis was underpowered as observed in the comparison of trial arms in the nasopharyngeal

swabs, esp current analysis was underpowered as observed in the comparison of trial arms in the nasopharyngeal
273 swabs, especially in newborns. This was an opportunistic study and oropharyngeal rather than
274 nasopharyngeal sample swabs, especially in newborns. This was an opportunistic study and oropharyngeal rather than

nasopharyngeal samples may have been more appropriate for detecting *S. pyogenes* carriage [4

adds to the growing evidence that nasopharyngeal samples may have been more appropriate for detecting *S. pyogenes* carriage [42], but

adds to the growing evidence that group A *Streptococcus* may include SDSE as well as *S. pyogenes*.

In conclusion, thi 275 adds to the growing evidence that group A *Streptococcus* may include SDSE as well as *S. pyogenes*.

276 In conclusion, this study demonstrates that a simple intervention (single dose of intra-partum oral

277 azithro In conclusion, this study demonstrates that a simple intervention (single dose of intra-partum oral

277 azithromycin), besides reducing carriage of *S. aureus*, *S. pneumoniae* and GBS, can also reduce ca

278 of GAS, an 277 azithromycin), besides reducing carriage of *S. aureus, S. pneumoniae* and GBS, can also reduce carriage
278 of GAS, an important cause of maternal and neonatal sepsis. We need to closely monitor the effect of this
279 278 of GAS, an important cause of maternal and neonatal sepsis. We need to closely monitor the effect of this
279 prophylactic intervention on azithromycin-resistant SDSE(A) isolates and its effect on disease when
280 asse

prophylactic intervention on azithromycin-resistant SDSE(A) isolates and its effect on disease when
assessing the overall public health potential of prophylactic intra-partum azithromycin.
Supplementary Data
Supplementar 280 assessing the overall public health potential of prophylactic intra-partum azithromycin.
281 **Supplementary Data**
282 Supplementary 1: WGS_data.xlsx
283

281 **Supplementary Data** 283

284 *Author's contributions*
285 AR and UDA conceiver
286 wrote the manuscript a
287 developed and adapted
288 team that conducted the
389 statistical input to the str 285 AR and UDA conceived and designed the initial trial. AR, IJ and TdS conceived this posthoc study. IJ
286 wrote the manuscript and AR, TdS, AJK contributed significantly in the final version. CO, BC, AB
287 developed an wrote the manuscript and AR, TdS, AJK contributed significantly in the final version. CO, BC, AB
developed and adapted the field and laboratory work. IJ, EJ and ES analysed the samples. AKS led the
team that conducted the developed and adapted the field and laboratory work. IJ, EJ and ES analysed the samples. AKS led the

288 team that conducted the WGS. AJK, SYB, CET and TdS performed the WGS analysis. CB provided

289 statistical input to

team that conducted the WGS. AJK, SYB, CET and TdS performed the WGS analysis. CB provided

statistical input to the study. All authors read and approved the final manuscript.

Acknowledgements

The authors express our pro 289 statistical input to the study. All authors read and approved the final manuscript.

290 Acknowledgements

291 The authors express our profound gratitude to the study participants and their fan

292 part in the study. 290 *Acknowledgements*
291 The authors express
292 part in the study. We
293 Kumba Baldeh, Moc
294 sample reception and
295 the MRCG genomic:
296 the field team (led b) The authors express our profound gratitude to the study participants and their families for agreeing to take

292 part in the study. We give special thanks to the laboratory team (Njemmeh Manneh, Aji Mary Taal, Aru

293 Ku 292 part in the study. We give special thanks to the laboratory team (Njemmeh Manneh, Aji Mary Taal, Aru

293 Kumba Baldeh, Modou Lamin Fofana, Momodou Abass Bah and Nano Kora) for their involvement in

294 sample receptio Xumba Baldeh, Modou Lamin Fofana, Momodou Abass Bah and Nano Kora) for their involvement in
294 sample reception and processing. We also extend our gratitude to Jarra Manneh and Abdoulie Kanteh c
295 the MRCG genomics team 294 sample reception and processing. We also extend our gratitude to Jarra Manneh and Abdoulie Kanteh of
295 the MRCG genomics team, Nuredin Ibrahim Mohammed for assisting with generating some figures and
296 the field tea

the MRCG genomics team, Nuredin Ibrahim Mohammed for assisting with generating some figures and

296 the field team (led by Edrissa Sabally and Omar Jarra) for assisting with sample collection.

297 *Financial support*

29 the field team (led by Edrissa Sabally and Omar Jarra) for assisting with sample collection.

297 Financial support

298 The MRC Unit in The Gambia at LSHTM receives core funding from the MRC UK. The t

299 funded by the M 297 **Financial support**
298 The MRC Unit in 7
299 funded by the MF
300 MRC/DFID Conce
201 HEFCE/ODA gran
302 Intermediate Clinic
2037 Dale Fellow (2087) The MRC Unit in The Gambia at LSHTM receives core funding from the MRC UK. The trial was jointly

1999 funded by the MRC UK and the UK Department for International Development (DFID) under the

1900 MRC/DFID Concordat agre 299 funded by the MRC UK and the UK Department for International Development (DFID) under the

200 MRC/DFID Concordat agreement (reference number MR/J010391/1). The WGS was funded by a

201 HEFCE/ODA grant from The Univers 300 MRC/DFID Concordat agreement (reference number MR/J010391/1). The WGS was funded by a
301 HEFCE/ODA grant from The University of Sheffield (155123). TdS is funded by a Wellcome Trust
302 Intermediate Clinical Fellowshi 301 HEFCE/ODA grant from The University of Sheffield (155123). TdS is funded by a Wellcome Trust
302 Intermediate Clinical Fellowship (110058/Z/15/Z). CET is a Royal Society & Wellcome Trust Sir Henry
303 Dale Fellow (2087 302 Intermediate Clinical Fellowship (110058/Z/15/Z). CET is a Royal Society & Wellcome Trust Sir Henry
303 Dale Fellow (208765/Z/17/Z).
304 *Potential conflicts of interest*
305 All authors declare no conflicts of interes

203 Dale Fellow (208765/Z/17/Z).
304 *Potential conflicts of interest*
305 All authors declare no conflicts 304 *Potential conflicts of interest* 305 All authors declare no conflicts of interest

306

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2020.12.04.20236653;](https://doi.org/10.1101/2020.12.04.20236653) this version posted December 7, 2020. The copyright holder for this preprint

-
-
- 313 1. Material $\frac{1}{\sqrt{2}}$ and $\frac{1}{\sqrt{2}}$ at $\frac{1}{\sqrt{2}}$ and $\frac{1}{\sqrt{2}}$ and 310 2. Say L, Chou D, Gemmill A, et al. Globe
311 Lancet Glob Health 2014; 2(6): e32
312 3. Shah BA, Padbury JF. Neonatal sep
313 170-8. 311 Lancet Glob Health 2014; 2(6): e323-33.
312 3. Shah BA, Padbury JF. Neonatal sepsis: an old problem with new insights. Virulence 2014; 5(1)
313 170-8.
314 4. UNICEF. Under-five Mortality. Available at: https://data.uni 312 3. Shah BA, Padbury JF. Neonatal sepsis: an
313 170-8.
314 4. UNICEF. Under-five Mortality. Available a
5 five-mortality/. Accessed 20/01/2020.
- 313 17 1008.
314 4. UNICEF. Under-five Mortality. Available at: https://data.unicef.org/topic/child-survival/under-
315 15 15 15 16 16 17 2020.
316 5. Knowles SJ, O'Sullivan NP, Meenan AM, Hanniffy R, Robson M. Maternal se 314 4. UNICER

315 <u>five-mo</u>

315 <u>five-mo</u>

316 5. Knowle

317 aetiolo

318 6 Simons
-
-
- 319 Microbiol Rev 2014; 27(1): 21-47. 316 5. Knowles SJ, O'Sullivan NP, Meenan AM
aetiology and outcome for mother and
318 6. Simonsen KA, Anderson-Berry AL, Dela
319 Microbiol Rev 2014; 27(1): 21-47. 5. Knowles SJ, O'Sullivan NP, Meenan AM, Hanniffy R, Robson M. Maternal sepsis incidence,
317 aetiology and outcome for mother and fetus: a prospective study. BJOG **2015**; 122(5): 663
318 6. Simonsen KA, Anderson-Berry AL, 318 6. Simonsen KA, Anderson-Berry AL, Delair SF, Davies HD. Early-onset neonatal sepsis. Clin
319 Microbiol Rev 2014; 27(1): 21-47.
320 7. Okomo U, Akpalu ENK, Le Doare K, et al. Aetiology of invasive bacterial infection 319 Microbiol Rev 2014; 27(1): 21-47.
320 7. Okomo U, Akpalu ENK, Le Doare K, et al. Aetiology of invasive bacterial infection and
321 antimicrobial resistance in neonates in sub-Saharan Africa: a systematic review and met
-
-
- 22 Microbiol Rev 2014, 27, 21, 22, 23
321 antimicrobial resistance in neonat
322 analysis in line with the STROBE-N
323 19(11): 1219-34.
324 8. Ekelund K, Skinhoj P, Madsen J, Ko
-
-
- 321 antimicrobial resistance in neonates in sub-Saharan Africa: a systematic review and n
322 analysis in line with the STROBE-NI reporting guidelines. The Lancet Infectious Diseas
323 19(11): 1219-34.
324 8. Ekelund K, Sk 323 19(11): 1219-34.
324 8. Ekelund K, Skinhoj P, Madsen J, Konradsen HB. Invasive group A, B, C and G streptococcal
325 infections in Denmark 1999-2002: epidemiological and clinical aspects. Clin Microbiol Infect
326 2005 324 8. Ekelund K, Skinho
325 infections in Den
326 2005; 11(7): 569-325 infections in Denmark 1999-2002: epidemiological and clinical aspects. Clin Microbiol Infe
 2005; 11(7): 569-76.

17
- 326 2005; 11(7): 569-76.

17 326 2005; 11(7): 569-76.

-
-
- 328 epidemiology of beta-haemolytic streptococcal bacteraemia: a population-based study
329 Microbiol Infect 2009; 15(3): 286-8.
330 10. Anderson BL. Puerperal group A streptococcal infection: beyond Semmelweis. Obstet G
3
- 329 Microbiol Infect 2009; 15(3): 286-8.
330 10. Anderson BL. Puerperal group A streptococcal infection: beyond Semmelweis. Obstet Gynece
331 2014; 123(4): 874-82.
332 11. Ronchetti MP, Bersani I, Piersigilli F, Auriti C. 2330 10. Anderson BL. Puerperal group A stre

331 2014; 123(4): 874-82.

332 11. Ronchetti MP, Bersani I, Piersigilli F,

333 Developmental Pathology 2017; 1(3
- 2014; 123(4): 874-82.
332 11. Ronchetti MP, Bersani I, Piersigilli F, Auriti C. Neonatal Sepsis. Archives of Paediatrics and
333 Developmental Pathology 2017; 1(3): 1015.
334 12. Revelas A, Taxmazidis O. Group A streptococ 232 11. Ronchetti MP, Bersani
332 11. Ronchetti MP, Bersani
333 Developmental Pathol
334 12. Revelas A, Taxmazidis
335 of Epidemiology and II 333 Developmental Pathology 2017; 1(3): 1015.
334 12. Revelas A, Taxmazidis O. Group A streptococcal infections in children. Southern African Jo
335 of Epidemiology and Infection 2015; 27(3): 98-103.
336 13. Chuang I, Van 334 12. Revelas A, Taxmazidis O. Group A streptococord Felidemiology and Infection 2015; 27(3): 9
335 of Epidemiology and Infection 2015; 27(3): 9
336 13. Chuang I, Van Beneden C, Beall B, Schuchat.
337 invasive group a st
- of Epidemiology and Infection 2015; 27(3): 98-103.
336 13. Chuang I, Van Beneden C, Beall B, Schuchat A. Population-based surveillance for postpartum
337 invasive group a streptococcus infections, 1995-2000. Clin Infect Di 336 13. Chuang I, Van Beneden C, Beall B, Schuchat A. Popular invasive group a streptococcus infections, 1995-200
337 invasive group a streptococcus infections, 1995-200
338 14. Hamilton SM, Stevens DL, Bryant AE. Pregnanc 337 invasive group a streptococcus infections, 1995-2000. Clin Infect Dis 2002; 35(6): 665-70.
338 14. Hamilton SM, Stevens DL, Bryant AE. Pregnancy-related group a streptococcal infections:
339 temporal relationships betw
-
-
-
-
- 338 14. Hamilton SM, Stevens DL, Bryant AE. Pregnancy-related group a streptococcal infections:
339 temporal relationships between bacterial acquisition, infection onset, clinical findings, and
340 outcome. Clin Infect Dis 339 14. Hamman enty-relationships between bacterial acquisition, infection onset, clinical findings, and outcome. Clin Infect Dis 2013; 57(6): 870-6.
341 15. Leonard A, Wright A, Saavedra-Campos M, et al. Severe group A st 340 outcome. Clin Infect Dis 2013; 57(6): 870-6.
341 15. Leonard A, Wright A, Saavedra-Campos M, et al. Severe group A streptococcal infections in
342 mothers and their newborns in London and the South East, 2010-2016: ass
- 341 15. Leonard A, Wright A, Saavedra-Campos M, e
mothers and their newborns in London and
343 audit of public health management. BJOG 20
344 16. Barth DD, Engel ME, Whitelaw A, et al. Ratio
345 infection registry: the AFR 342 mothers and their newborns in London and the South East, 2010-2016: assessment of risk a

343 audit of public health management. BJOG 2019; 126(1): 44-53.

344 16. Barth DD, Engel ME, Whitelaw A, et al. Rationale and d 343

343 audit of public health management. BJOG 2019; 126(1): 44-53.

344 16. Barth DD, Engel ME, Whitelaw A, et al. Rationale and design of the African group A streptococc

345 infection registry: the AFROStrep study. BM 344 16. Barth DD, Engel ME, Whitelaw A, et al. Rationale and design of
infection registry: the AFROStrep study. BMJ Open 2016; 6(2): ϵ 345 Infection registry: the AFROStrep study. BMJ Open 2016; 6(2): e010248.
345 Infection registry: the AFROStrep study. BMJ Open 2016; 6(2): e010248.

 345 infection registry: the AFROSTREP study. BMJ \sim (2): end 2016; 6(2): \sim

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2020.12.04.20236653;](https://doi.org/10.1101/2020.12.04.20236653) this version posted December 7, 2020. The copyright holder for this preprint

-
-
-
-
- 351 19. Belard S, Toepfner N, Arnold B, Alabi AS, Berner R. beta-Hemolytic streptococcal throat carriage 348 2003–2015. Southern African Journal of Infectious Diseases 2017; 33(1): 12-7.
349 18. Seale AC, Davies MR, Anampiu K, et al. Invasive Group A Streptococcus Infection among
350 Children, Rural Kenya. Emerg Infect Dis 20 349 18. Seale AC, Davies MR, Anampiu K, et al. Invasive Group A Streptococcus Infection
350 Children, Rural Kenya. Emerg Infect Dis 2016; 22(2): 224-32.
351 19. Belard S, Toepfner N, Arnold B, Alabi AS, Berner R. beta-Hemo 350 Children, Rural Kenya. Emerg Infect Dis 2016; 22(2): 224-32.
351 19. Belard S, Toepfner N, Arnold B, Alabi AS, Berner R. beta-Hemolytic streptococcal throat candidation and tonsillopharyngitis: a cross-sectional preval 351 19. Belard S, Toepfner N, Arnold B, Alabi AS, Berner R. beta-Hem
352 and tonsillopharyngitis: a cross-sectional prevalence study in
353 2015; 43(2): 177-83.
354 20. Armitage EP, Senghore E, Darboe S, et al. High burden
-
-
- and tonsillopharyngitis: a cross-sectional prevalence study in Gabon, Central Africa. Infection

2015; 43(2): 177-83.

354 20. Armitage EP, Senghore E, Darboe S, et al. High burden and seasonal variation of paediatric

sca 2015; 43(2): 177-83.
353 2015; 43(2): 177-83.
354 20. Armitage EP, Senghore E, Darboe S, et al. High burden and seasonal variation of paediatric
355 scabies and pyoderma prevalence in The Gambia: A cross-sectional study. P Example 1994, 2015

354 20. Armitage EP, Sengho

355 scabies and pyoderm

356 2019; 13(10): e00078

357 21. Roca A, Oluwalana C,

delivery administration 355 32019; 13(10): e0007801.
355 32019; 13(10): e0007801.
356 2019; 13(10): e0007801.
357 21. Roca A, Oluwalana C, Camara B, et al. Prevention of bacterial infections in the newborn by delivery administration of azithromyc
- 2019; 13(10): e0007801.
357 21. Roca A, Oluwalana C, Camara B, et al. Prevention of bacterial infections in the newborn by pre
358 delivery administration of azithromycin: Study protocol of a randomized efficacy trial. BMC
-
- 2020 2022, 2019; 2020

357 21. Roca A, Oluwalana C, Car

358 delivery administration of

359 Pregnancy Childbirth 201

360 22. Roca A, Oluwalana C, Boj.

361 carriage in the mothers a 359 Pregnancy Childbirth 2015; 15: 302.
360 22. Roca A, Oluwalana C, Bojang A, et al. Oral azithromycin given during labour decreases bacte
361 carriage in the mothers and their offspring: a double-blind randomized trial. 2380 22. Roca A, Oluwalana C, Bojang A, et al
361 carriage in the mothers and their off
362 2016; 22(6): 565 e1-9.
363 23. Oluwalana C, Camara B, Bottomley C
364 Mothers and Newborns: A Double-B 361 carriage in the mothers and their offspring: a double-blind randomized trial. Clin Microbiol Infectory 2016; 22(6): 565 e1-9.
363 23. Oluwalana C, Camara B, Bottomley C, et al. Azithromycin in Labor Lowers Clinical Inf
-
- 2016; 22(6): 565 e1-9.
363 23. Oluwalana C, Camara B, Bottomley C, et al. Azithromycin in Labor Lowers Clinical Infections in
364 Mothers and Newborns: A Double-Blind Trial. Pediatrics 2017; 139(2).
365 24. Bolger AM, Lohs 222, 23. Oluwalana C, Camara E
363 23. Oluwalana C, Camara E
365 24. Bolger AM, Lohse M, U
366 Bioinformatics 2014; 3 364 Mothers and Newborns: A Double-Blind Trial. Pediatrics 2017; 139(2).
365 24. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data.
366 Bioinformatics 2014; 30(15): 2114-20.
19 365 24. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for IIIu
366 Bioinformatics 2014; 30(15): 2114-20.
39 366 Bioinformatics 2014; 30(15): 2114-20.
19 366 Bioinformatics 2014; 30(15): 2114-20.

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2020.12.04.20236653;](https://doi.org/10.1101/2020.12.04.20236653) this version posted December 7, 2020. The copyright holder for this preprint

-
-
-
-
-
- 368 applications to single-cell sequencing. Journal of computational biology : a journal of
369 computational molecular cell biology 2012; 19(5): 455-77.
370 26. Gurevich A, Saveliev V, Vyahhi N, Tesler G. QUAST: quality a 369 computational molecular cell biology 2012; 19(5): 455-77.
370 26. Gurevich A, Saveliev V, Vyahhi N, Tesler G. QUAST: quality assessment tool for genom
371 assemblies. Bioinformatics 2013; 29(8): 1072-5.
372 27. Seemann
- 370 26. Gurevich A, Saveliev V, Vyahhi N, Tesler G. QUAST: quality
371 assemblies. Bioinformatics 2013; 29(8): 1072-5.
372 27. Seemann T. Prokka: rapid prokaryotic genome annotation.
373 28. Page AJ, Cummins CA, Hunt M, et 371 assemblies. Bioinformatics 2013; 29(8): 1072-5.
372 27. Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics 2014; 30(14):
373 28. Page AJ, Cummins CA, Hunt M, et al. Roary: rapid large-scale prokaryo
- 372 27. Seemann T. Prokka: rapid prokaryotic genome a
373 28. Page AJ, Cummins CA, Hunt M, et al. Roary: rapid
374 Bioinformatics 2015; 31(22): 3691-3.
375 29. Zankari E, Hasman H, Cosentino S, et al. Identific 373 28. Page AJ, Cummins CA, Hunt M, et al. Roary: rapid large-scale prokaryote pan genome analysis.
374 Bioinformatics 2015; 31(22): 3691-3.
375 29. Zankari E, Hasman H, Cosentino S, et al. Identification of acquired anti 375 29. Zankari E, Hasman H, Cosentino S, et
376 genes. J Antimicrob Chemother 2012
377 30. Karsnitz DB. Puerperal infections of the Health 2013; 58(6): 632-42.
- 374 Bioinformatics 2015; 31(22): 3691-3.
375 29. Zankari E, Hasman H, Cosentino S, et al. Identification of acquired antimicrobial resistance
376 genes. J Antimicrob Chemother 2012; 67(11): 2640-4.
377 30. Karsnitz DB. Pue 377 30. Karsnitz DB. Puerperal infections of the genital tract: a
378 Health 2013; 58(6): 632-42.
379 31. Stamatakis A. RAxML version 8: a tool for phylogenetic
380 phylogenies. Bioinformatics (Oxford, England) 2014; 31
38
-
- 376 2012, Standard President 2012; 67(11): 2640-4.
377 30. Karsnitz DB. Puerperal infections of the genital tract: a clinical review. J Midwifery Women:
378 Health 2013; 58(6): 632-42.
379 31. Stamatakis A. RAxML version 8
- 378 Health 2013; 58(6): 632-42.
379 31. Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large
380 phylogenies. Bioinformatics (Oxford, England) 2014; 30(9): 1312-3.
381 32. Chochua S, R 379 31. Stamatakis A. RAxML version

380 phylogenies. Bioinformatics

381 32. Chochua S, Rivers J, Mathis

382 subsp. equisimilis, United St

383 33 Salman S, Davis TM, Page-Sk 380 phylogenies. Bioinformatics (Oxford, England) 2014; 30(9): 1312-3.
381. 32. Chochua S, Rivers J, Mathis S, et al. Emergent Invasive Group A Streptococcus dysgalactiae
382 subsp. equisimilis, United States, 2015-2018. E 381 32. Chochua S, Rivers J, Mathis S, et al. Emergent Invasive Group A Stre
382 subsp. equisimilis, United States, 2015-2018. Emerg Infect Dis 2019
383 33. Salman S, Davis TM, Page-Sharp M, et al. Pharmacokinetics of Tran subsp. equisimilis, United States, 2015-2018. Emerg Infect Dis 2019; 25(8): 1543-7.

383. Salman S, Davis TM, Page-Sharp M, et al. Pharmacokinetics of Transfer of Azithromycin into

384. Sreast Milk of African Mothers. Ant
- 383 33. Salman S, Davis TM, Page-Sharp M, et al. Pharmacokinetics of Transfer of Azithrom
384 Breast Milk of African Mothers. Antimicrob Agents Chemother 2015; 60(3): 1592-9.
385 34. Vodstrcil LA, Rupasinghe TWT, Kong FYS,
-
- 384 Breast Milk of African Mothers. Antimicrob Agents Chemother 2015; 60(3): 1592-9.
385 34. Vodstrcil LA, Rupasinghe TWT, Kong FYS, et al. Measurement of tissue azithromycin levels in
386 self-collected vaginal swabs post 385 34. Vodstrcil LA, Rupasinghe TWT, Kong FYS, et al. Measurement of tissue azithromycin self-collected vaginal swabs post treatment using liquid chromatography and tander spectrometry (LC-MS/MS). PLoS One 2017; 12(5): e0 self-collected vaginal swabs post treatment using liquid chromatography and tandem mass
spectrometry (LC-MS/MS). PLoS One 2017; 12(5): e0177615.
20 387 spectrometry (LC-MS/MS). PLoS One 2017; 12(5): e0177615.
20
- $\frac{38}{20}$

409

^aEthnicity missing in n=3, b </sup>

^aCarriage at day 0 before treatment

^bCarriage at days 3, 6, 14 and 28 combined

414 ^aCarriage at day 0 before treatment
415 ^bCarriage at days 3, 6, 14 and 28 co
416 ^c There are no pre-intervention samy
417 ^dDay 10(day 8 – 13) 415 $^{\circ}$ Carriage at days 3, 6, 14 and 28 combined
416 $^{\circ}$ There are no pre-intervention samples for t
417 $^{\circ}$ Day 10(day 8 – 13) ^c There are no pre-intervention samples for the breast milk 416 ° There are no pre-intervention samples for the breast milk 4 Day 10(day 8 – 13) 2.

 $\text{day } 10 \text{ (day } 8 - 13)$ 417 a^4 Day 10(day 8 – 13)

- e^{c} Day 0, 3,6,14 and 28 combined. Day 0 is the day of birth
-
-
- 420
421
422
- ^aCarriage at day 0 before treatment

Carriage at days 3, 6, 14 and 28 combined

^c There are no pre-intervention samples for the breast milk

 $\text{day } 10 \text{ (day } 8 - 13)$

423 $^{\circ}$ Carriage at days 3, 6, 14 and 28 combined
424 $^{\circ}$ There are no pre-intervention samples for 4 Day 10(day 8 – 13)
425 $^{\circ}$ Day 0, 3,6,14 and 28 combined. Day 0 is th
427 424 ° There are no pre-intervention samples for the breast milk
425 4 Day 10(day 8 – 13)
426 ° Day 0, 3,6,14 and 28 combined. Day 0 is the day of birth
427 425 4 Day 10(day 8 – 13)
426 4 Day 0, 3,6,14 and 28
427 ^eDay 0, 3,6,14 and 28 combined. Day 0 is the day of birth 426 ° Day 0, 3,6,14 and 28 combined. Day 0 is the day of birth 427

-
- 428 Figure 1: Trial profile
429 $\frac{1}{1}$ Mother/baby pair with ≥ 1
430 1 429 $\frac{1}{2}$ Mother/baby pair with ≥1 missing sample 430

-
- 431 Figure 2: (a) Prevalence of i) maternal nasopharyngeal carriage and ii) breastmilk carriage of GAS at different timepoints in the azithromycin and placebo arms. (b) Prevalence of neonatal nasopharyngeal carriage of GAS 432 GAS at different timepoints in the azithromycin and placebo arms. (b) Prevalence of neonatal nasopharyngeal carriage of GAS at different timepoints in the azithromycin and placebo arms
434
434
- 433 nasopharyngeal carriage of GAS at different timepoints in the azithromycin and placebo arms

-
-
-
- 437 bootstrap support. (a) Core-genome (1299 genes) phylogenetic analysis of 35 *S. pyogenes* isolates from the study cohort. (b) International contextualization (based on core genome of 1221 genes) of 10 *S. dysgalactiae*
- Figures 3: Midpoint rooted maximum likelihood core-genome phylogenetic analysis using
RAxML GTRCAT model with 1000 bootstrap replicates. Circle symbols indicate >99%
bootstrap support. (a) Core-genome (1299 genes) phylogen RAxML GTRCAT model with 1000 bootstrap replicates. Circle symbols indicate >99%
bootstrap support. (a) Core-genome (1299 genes) phylogenetic analysis of 35 *S. pyogenes*
from the study cohort. (b) International contextuali from the study cohort. (b) International contextualization (based on core genome of 1221 genes)
of 10 *S. dysgalactiae* subspecies *equisimilis* isolates with individual core-genome (upper clade:
2106 genes, lower clade: 2
- 439 of 10 *S. dysgalactiae* subspecies *equisimilis* isolates with individual core-genome (upper clade: 2106 genes, lower clade: 2078 genes) phylogenetic analysis of the two distinct clades in the study cohort. (Annotation
-
- 441 study cohort. (Annotation key: country of origin; black=the Gambia, yellow=USA, dark
442 green=UK, light green=Germany, pink=Japan, white=unknown, symbols; filled=present.
443 unfilled=absent, no symbol=unknown; study 442 green=UK, light green=Germany, pink=Japan, white=unknown, symbols; filled=present, unfilled=absent, no symbol=unknown; study participant ID (unique study identifier for mother/baby units); M=mother, B=newborn, NPS=naso
-
- 2106 genes, lower clade: 2078 genes) phylogenetic analysis of the two distinct clades in the study cohort. (Annotation key: country of origin; black=the Gambia, yellow=USA, dark green=UK, light green=Germany, pink=Japan, w 443 unfilled=absent, no symbol=unknown; study participant ID (unique study identifier for mother/baby units); M=mother, B=newborn, NPS=nasopharyngeal swab, VS=vaginal s
BM=breast milk, AMR=antimicrobial resistance).
 $\frac{1}{$ 444 mother/baby units); M=mother, B=newborn, NPS=nasopharyngeal swab, VS=vaginal swab, BM=breast milk, AMR=antimicrobial resistance).
- 445 BM=breast milk, AMR=antimicrobial resistance).

NPS

 $\sim 10^{-11}$

NPS

 $\begin{array}{c}\n\hline\n- \rightarrow 0.001\n\end{array}$

0.001

 I_{-} $=$ $SRR7706919$

